

10 September 2024

2024 ANNUAL GENERAL MEETING – KEY DATES

In accordance with ASX Listing Rule 3.13.1, Botanix Pharmaceuticals Ltd (ASX:BOT) (“**Botanix**” or the “**Company**”) is pleased to announce the 2024 Annual General Meeting has been scheduled for 9.00am (WST) on Monday, 4 November 2024 at the offices of BDO, Level 9, Mia Yellagonga Tower 2, 5 Spring Street, Perth, Western Australia.

An item of business at the AGM will be the re-election of directors. The closing date for the receipt of director nominations is 16 September 2024. Nominations must be received at the Company’s registered office no later than 5.00pm (WST) on 16 September 2024.

Further information on the Annual General Meeting will be provided in the Notice of Annual General Meeting which will be released to ASX on or before Thursday, 3 October 2024.

Release authorised by the Board of Directors.

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Ltd (ASX:BOT) is a dermatology company based in Philadelphia and Phoenix (US) which has received FDA approval for its lead product Sofdra™ for the treatment of primary axillary hyperhidrosis. Sofdra™ is the first and only new chemical entity approved by FDA to treat primary axillary hyperhidrosis and presents a novel safe and effective solution for patients who have lacked treatment options for this socially challenging medical condition.

To learn more please visit: <http://www.botanixpharma.com/>

For more information, please contact:

General enquiries

Corporate Communications
Botanix Pharmaceuticals
P: +61 8 6555 2945
investors@botanixpharma.com

Investor enquiries

Hannah Howlett
WE Communications
P: +61 450 648 064
hhowlett@we-worldwide.com

Media enquiries

Haley Chartres
H^CK
P: +61 423 139 163
haley@hck.digital